Ceragon網絡 CRNT 深 滬
等待開盤 08-14 09:30:00 美东时间
2.05
+0.110
+5.67%
華盛通- 最 高2.06
- 今 開1.98
- 成交量 63.85万股
- 最 低 1.93
- 昨 收 1.94
- 總市值 1.82亿
- 52周最高 5.73
- 市盈率 靜 7.59
- 換手率 0.72%
- 52周最低 1.82
- 委 比 -0.24%
- 總股本 8892.97万
- 歷史最高 12.21
- 量 比 0.60
- 振 幅 6.70%
- 歷史最低 0.88
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ceragon Networks Secures $8 Million Network Modernization Project in EMEA
Ceragon Networks ( ($CRNT) ) has issued an announcement. On August 13, 2025, Ce...
08-13 20:28
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported Q2 2025 financial results, highlighting progress toward its acromegaly drug PALSONIFY™ with an FDA PDUFA date of Sept 25, 2025. The company advanced multiple clinical programs, including atumelnant for CAH, and presented data at major medical meetings. Cash reserves of $1.2B are expected to support operations into 2029.
08-07 20:05
Ceragon Networks shares are trading lower after the company reported worse-than-expected Q2 financial results.
Ceragon Networks shares are trading lower after the company reported worse-than...
08-06 20:42
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
美股大行评级 | 潜在涨幅163.16%！Craig-Hallum上调DiaMedica Therapeutics目标价至11美元，维持"买入"评级
今日重点评级关注：Craig-Hallum：维持DiaMedica Therapeutics"买入"评级，目标价从8美元升至11美元；花旗：维持Cogent Biosciences"买入"评级，目标价从15美元升至22美元
07-21 09:19
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Data from Crinetics' clinical trials show that PALSONIFY (paltusotine), an oral treatment for acromegaly, demonstrated durable control of IGF-1 levels, reduced symptom burden, and was well-tolerated during long-term use. Results from the PATHFNDR-1 and PATHFNDR-2 open-label extensions, presented at ENDO 2025, highlight PALSONIFY's potential as a next-generation therapy for acromegaly. In PATHFNDR-1, 91% of participants transitioned to the open-...
07-13 21:45
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
<p>Cisinetics Pharmaceuticals announced it will report its second quarter 2025 financial results on August 7, 2025 after market close. The company will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Participants can join via phone using domestic number 1 833-470-1428 or international number 1 404-975-4839 with access code 899803. The call will also be webcast live and archived on the company's website...
07-11 12:00
Mahindra Selects Cerence Audio AI to Power In-Car Voice Interaction in its Electric Origin SUVs
Mahindra introduces two new eSUVs, the BE 6 and XEV 9e, featuring Cerence Audio AI, a cutting-edge speech enhancement technology. This partnership aims to improve in-car communication, particularly in noisy environments, by leveraging Cerence Speech Signal Enhancement (SSE) for clear interactions between drivers, passengers, and the infotainment system. Mahindra's MAIA architecture, combined with Cerence's technology, offers an intelligent, conne...
07-01 12:00
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
<p>San Diego, June 30, 2025. Crinetics Pharmaceuticals announced eight abstracts from its novel clinical programs, including PALSONIFY™ (paltusotine) and atumelnant, will be presented at ENDO 2025 in San Francisco. PALSONIFY continues to show long-term efficacy and safety in acromegaly patients, whether switching treatments or newly untreated. Atumelnant’s Phase 2 results in congenital adrenal hyperplasia (CAH) will be highlighted, along with upd...
06-30 20:05
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Crinetics Pharmaceuticals will host an in-person and virtual R&D Day on June 26, 2025, in New York. The event will provide updates on their early-stage pipeline assets, including NETs with CRN09682, Graves' disease, and ADPKD. A live Q&A session will follow. Registration is available through the provided link.
06-16 12:00
